Local Literature Monitoring
Capture local safety insights before they reach global sources if at all
Local medical literature remains one of the most valuable yet challenging sources of pharmacovigilance information. Many adverse events, safety observations, and clinically relevant related to human and veterinary medicinal products are published exclusively in local journals and may never appear in global databases such as PubMed or Embase.
MS Pharm provides comprehensive Local Literature Monitoring designed specifically for pharmaceutical and safety teams that require reliable, compliant, and inspection-ready results. Our service combines automation with the expertise of native-language reviewers who perform intellectual review of full-text articles, ensuring that safety-relevant information is identified accurately and efficiently.
What makes our approach different?
Unlike services based solely on keyword screening or abstract review, MS Pharm evaluates complete journal and article content. Every article is assessed for adverse events, adverse drug reactions, special situations, product quality issues, and potential safety signals related to human and veterinary medicinal products. Relevant findings are indexed, classified, and documented within our validated eDRUG platform, providing complete traceability and audit readiness.
Key benefits
- Full-text review of local medical, pharmaceutical and veterinary journals
- Native-language pharmacovigilance reviewers
- Identification of potential ICSRs and safety signals
- 24-hour reporting of potential valid ICSRs
- Weekly and monthly reconciliation reports
- Complete audit and inspection documentation
- Coverage of over 100 countries and more than 2,000 journals
Global Coverage. Local Expertise.
MS Pharm provides Local Literature Monitoring through a network of native-language reviewers and local pharmacovigilance experts covering more than 100 countries worldwide.
West Europe – Austria, Belgium, France, Germany, Ireland, Luxembourg, Netherlands, Switzerland, United Kingdom.
Nordics – Denmark, Finland, Iceland, Norway, Sweden.
Southern Europe – Cyprus, Greece, Italy, Malta, Portugal, Spain.
Central & Eastern Europe – Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia.
Balkans – Albania, Bosnia and Herzegovina, Montenegro, North Macedonia, Serbia.
CIS & Eurasia – Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Russia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan.
Middle East – Egypt, Iraq, Saudi Arabia, Turkey, United Arab Emirates.
Africa – English- and French-speaking countries.
Asia-Pacific – Australia, Nepal, Sri Lanka, Pakistan, Vietnam and others.
Americas – Canada and Latin America.
Why choose MS Pharm?
MS Pharm helps companies meet regulatory obligations while gaining valuable safety insights. Our combination of technology, expertise, and quality management ensures consistent, transparent, and reliable literature monitoring worldwide, supported by a GVP Compliance Certificate, more than 200 active projects, and a proven track record of successfully passed over 90 PV audits and tens of inspections.
Trusted by pharmaceutical companies worldwide
- 10+ years of MLM experience
- 100+ countries covered
- 2,000+ journals monitored
- 200+ active projects
- 90+ PV audits and dozens of inspections supported
- GVP-compliant processes
